Compare Abbott Laboratories (ABT) vs Payoneer Global Inc (PAYO) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Abbott Laboratories vs Payoneer Global Inc — how do they compare? Abbott Laboratories trades at $95.59 (market cap $166.94B), while Payoneer Global Inc trades at $7.1 (market cap $2.40B). The key difference: Abbott Laboratories is far larger — about 69.6× Payoneer Global Inc's market cap, and Abbott Laboratories pays a 2.63% dividend while Payoneer Global Inc pays none. Which is the better fit depends on your goals.
| ABT | PAYO | |
|---|---|---|
Market Cap | $166.94B | $2.40B |
Sector | Health | Technology |
52-Week High | $136.62 | $7.42 |
52-Week Low | $82.57 | $4.27 |
Enterprise Value | $193.69B | $2.14B |
Dividend Yield | 2.63% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Abbott Laboratories (ABT) trades at $95.63, up 0.25% on the day, with a bullish technical signal from moving averages and strong analyst support. The stock shows solid fundamentals with a P/E of 26.79 and net income margin of 13.91%, though recent earnings have been mixed. Recent news highlights regulatory approvals for new medical devices, supporting growth prospects.
The outlook remains positive with a consensus price target of $122.55, implying significant upside. Key risks include competitive pressures and macroeconomic headwinds, but strong institutional backing and consistent dividend payments provide stability for long-term investors.
Payoneer Global (PAYO) trades at $7.10, up slightly by 0.14% today, with a bullish technical signal from moving averages and a consensus analyst price target of $8.20. Recent financials show revenue growth to $821.16 million in 2025, though net income declined to $73.19 million, and the company is the subject of a pending $2.75 billion acquisition by Nuvei announced in June 2026.
The acquisition offer at $7.40 per share, below the consensus target, creates uncertainty but provides a near-term floor. Risks include integration challenges and shareholder litigation over deal fairness, while fundamentals like a 79.4% gross margin and positive cash flow support long-term value if the deal falls through.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Abbott Laboratories
Abbott manufactures and markets medical devices, adult and pediatric nutritional products, diagnostic equipment and testing kits, and branded generic drugs. Products include pacemakers, implantable cardioverter defibrillators, neuromodulation devices, coronary stents, catheters, infant formula, nutritional liquids for adults, molecular diagnostic platforms, and immunoassays and point-of-care diagnostic equipment. Abbott derives approximately 60% of sales outside the United States.
Read more on ABT →About Payoneer Global Inc
Payoneer Global Inc is the world's go-to partner for digital commerce, everywhere. The company started as a cross-border payments platform that empowers businesses, online sellers, and freelancers. The platform allows the users to get paid in multiple currencies, bill global clients, and sell on marketplaces worldwide.
Read more on PAYO →
